See more : Red Cat Holdings, Inc. (RCAT) Income Statement Analysis – Financial Results
Complete financial analysis of Axcella Health Inc. (AXLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axcella Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DT Cloud Acquisition Corporation (DYCQ) Income Statement Analysis – Financial Results
- Dynamic Precision Industry Corporation (8928.TWO) Income Statement Analysis – Financial Results
- Tondo Smart Ltd (TNDO.TA) Income Statement Analysis – Financial Results
- Nan Yang Dyeing & Finishing Co.,Ltd (1410.TW) Income Statement Analysis – Financial Results
- Bomin Electronics Co., Ltd. (603936.SS) Income Statement Analysis – Financial Results
Axcella Health Inc. (AXLA)
About Axcella Health Inc.
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.98M | 43.14M | 37.04M | 41.66M | 25.49M | 22.92M |
| General & Administrative | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Other Expenses | 0.00 | -4.00K | 10.00K | 34.00K | 0.00 | 0.00 |
| Operating Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Cost & Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Interest Income | 504.00K | 139.00K | 306.00K | 1.81M | 0.00 | 0.00 |
| Interest Expense | 3.02M | 2.92M | 3.01M | 3.40M | 0.00 | 0.00 |
| Depreciation & Amortization | 412.00K | 288.00K | 419.00K | 51.00K | 1.07M | 1.39M |
| EBITDA | -67.01M | -61.85M | -53.84M | -57.39M | -32.81M | -27.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.80M | -61.85M | -53.84M | -57.44M | -33.90M | -28.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.39M | -2.78M | -2.69M | -1.60M | -2.17M | -2.02M |
| Income Before Tax | -81.19M | -64.63M | -56.53M | -59.04M | -36.07M | -30.94M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.49M | 2.28M | 936.00K | -2.17M | 2.02M |
| Net Income | -81.19M | -67.12M | -58.81M | -59.97M | -36.07M | -30.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| EPS Diluted | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| Weighted Avg Shares Out | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
| Weighted Avg Shares Out (Dil) | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and year end 2021 financial...
Insiders Buy Over $7M Of 3 Penny Stocks
The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or...
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in...
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a...
Axcella (AXLA) Announces Fast Track Designation For AXA1125
Axcella Therapeutics (Nasdaq: AXLA) announced that the FDA has granted a Fast Track Designation to AXA1125. These are the details.
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track...
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast...
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference....
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the company’s new Chief Financial Officer. “Bob...
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the company's new Chief Financial Officer....
Source: https://incomestatements.info
Category: Stock Reports